Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers

Nature Reviews Drug Discovery

Volumn 6, Issue 4, 2007, Pages 287-293

  Trusheim, Mark R ^a   Berndt, Ernst R ^a   Douglas, Frank L ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BEVACIZUMAB; BIOLOGICAL MARKER; CELECOXIB; DROTRECOGIN; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IMIGLUCERASE; ORPHAN DRUG; PRAVASTATIN; SIMVASTATIN; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL DIAGNOSIS; DRUG CONTROL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG RESPONSE; FEASIBILITY STUDY; FRAGILITY FRACTURE; GENETIC ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; HYPERLIPIDEMIA; LUNG NON SMALL CELL CANCER; MEDICINE; PATIENT CARE; PATIENT SELECTION; PHARMACOGENOMICS; PRIORITY JOURNAL; REIMBURSEMENT; STRATIFIED MEDICINE;

BIOLOGICAL MARKERS; DECISION MAKING; DRUG INDUSTRY; DRUG THERAPY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 33947712686     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2251     Document Type: Article

References (14)

1. Belli, F. et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20, 4169-4180 (2002).
2. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1, 493-502 (2002).
3. Paoluzzi, L. et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN 38. J. Clin. Pharm. 44, 854-860 (2004).
4. Burstein, H. J. The distinctive nature of HER2-positive breast cancer. N. Engl. J. Med. 353, 1652-1654 (2005).
5. O'Neill, F. H. et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 21, 832-837 (2001).
6. Ordovas, J. M. & Mooser, V. B. The APOE locus and the pharmacogenetics of lipid response. Genetics and molecular biology. Curr. Opin. Lipidol. 13, 113-117 (2002).
7. Chasman, D. I. et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821-2827 (2004).
8. PGx Health. Biomarker development. PGx Health web site [online], (2006).
9. Dowell, J. E. & Minna, J. D. Chasing mutations in the epidermal growth factor in lung cancer. N. Engl. J. Med. 352, 830-832 (2005)
10. Rhee, S. Y. et al. HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J. Infect. Dis. 192, 456-465 (2005).
11. Roukos, D. H., Agnanti, N. J., Paraskevaidis. E. & Kappas, A. M. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann. Surg. Oncol. 9, 941-943 (2002).
12. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-186 (2003).
13. Grabowski, H. G. & Vernon, J. Longer patents for increased generic competition in the US - the Waxman-Hatch Act after one decade. Pharmacoeconomics 10, 110-123 (1996).
14. Grabowski, H. G. & Vernon, J. The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 18 (Suppl. 1), 21-32 (2000).